tumours

Pancreatic cancers are among the most aggressive, deadly tumous and, for years, researchers have struggled to develop effective drugs against them.

A new cancer therapy attacks tumours by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division.

A new study highlights the potential of artificial DNA structures that, when fitted with antibodies, instruct the immune system to specifically target cancerous cells.

A new approach developed by researchers at MIT and Dana-Farber Cancer Institute may make it easier to identify the sites of origin for enigmatic cancers.

Examining enzyme MAPK4, researchers have now identified a strategy that can potentially control MAPK4-promoted growth in triple negative breast cancer and other cancers.

For people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect: heart damage.

ICB therapy, which stands for immune checkpoint blockade, has become the standard treatment for lung cancer due to its generally positive outcomes.

A new nuclear medicine therapy can cure human non-Hodgkin lymphoma in an animal model.

Many cancer therapies do not produce the hoped-for results. A common reason for this is that the tumours develop resistance to the medication.

The breast tumours of Asian, Black and White women have very different cellular, microbial and genomic features.

Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumours in under 90 seconds.

Birmingham-based charity, Help Harry Help Others and Aston University researchers are working together to develop a pioneering pre-surgical diagnostic tool.

The technology allows for the enhanced delivery of anti-cancer drugs to the specific locations of brain tumours while sparing normal brain regions.

Melbourne researchers have improved our understanding of how the immune system is regulated to prevent disease.

Cancer is a disease driven by gene mutations. These mutated genes in cancer fall into two major categories: tumour suppressors and oncogenes.